for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Nantkwest Inc

NK.OQ

Latest Trade

1.11USD

Change

-0.05(-4.31%)

Volume

34,908

Today's Range

1.08

 - 

1.18

52 Week Range

0.93

 - 

4.08

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Nantkwest Inc Files For Mixed Shelf Of Up To $300 Mln

Aug 23 (Reuters) - NantKwest Inc <NK.O>::NANTKWEST INC FILES FOR MIXED SHELF OF UP TO $300 MILLION – SEC FILING.

Nantkwest Inc Says CEO Exercised Warrants With An Exercise Price Of $1.9984 & Options With An Exercise Price Of $2.1983

March 25 (Reuters) - NantKwest Inc <NK.O>::NANTKWEST CHAIRMAN & CEO DR. PATRICK SOON-SHIONG EXERCISES $39 MILLION IN WARRANTS AND OPTIONS IN SUPPORT OF NK’S NATURAL KILLER CELL STRATEGIC VISION BEYOND CHECK POINT IMMUNOTHERAPY.NANTKWEST INC - FUNDING TO SUPPORT INDS FOR FIRST-IN-HUMAN TARGETED OFF--SHELF NK CELLS (T-HANKS) WITH PD-L1 AND CD-19 AS TUMOR TARGETS.NANTKWEST INC - CHAIRMAN & CEO EXERCISED WARRANTS WITH AN EXERCISE PRICE OF $1.9984 AND OPTIONS WITH AN EXERCISE PRICE OF $2.1983.

Nantkwest Names Sonja Nelson Chief Financial Officer

June 19 (Reuters) - NantKwest Inc <NK.O>::NANTKWEST NAMES SONJA NELSON CHIEF FINANCIAL OFFICER.NELSON SUCCEEDS RICH TAJAK, WHO HAD SERVED AS COMPANY'S CFO SINCE JANUARY 2016.

Nantkwest Inc Appoints Sonja Nelson As CFO Effective June 11

June 13 (Reuters) - NantKwest Inc <NK.O>::NANTKWEST INC - EFFECTIVE AS OF JUNE 11, 2018, APPOINTED SONJA NELSON AS CHIEF FINANCIAL OFFICER.NANTKWEST SAYS EFFECTIVE AS OF JUNE 11, 2018, RICHARD TAJAK HAS STEPPED DOWN AS CFO- SEC FILING.

Nantkwest announces publication of preclinical data of hank cell therapy

July 25 (Reuters) - Nantkwest Inc <NK.O>::Nantkwest announces publication of preclinical data of hank cell therapy in combination with checkpoint inhibitor avelumab providing strong rationale for advancement to human clinical trials.

NantKwest expands nant cancer vaccine program

June 6 (Reuters) - Nantkwest Inc <NK.O>::NantKwest expands nant cancer vaccine program with additional clinical trials announced addressing multiple cancer types across all stages of disease.NantKwest Inc - expansion of company's existing nant cancer vaccine program in pancreatic cancer to target a number of additional tumor types.NantKwest - first combination off shelf NK, adaptive immunotherapy trial to be initiated for pancreatic, lung, breast and colon cancer, among others.

Nantkwest and Nantcell announce FDA authorization for Nant Cancer vaccine clinical trials

May 9 (Reuters) - Nantkwest Inc <NK.O>:Nantkwest and nantcell announce fda authorization for the nant cancer vaccine clinical trials, the first novel combination of innate and adaptive immunotherapy in patients with pancreatic cancer.

NantKwest and Viracta Therapeutics report series B financing

NantKwest Inc <NK.O>: NantKwest and Viracta Therapeutics announce series b financing and immunotherapy partnership .NantKwest - co, Viracta Therapeutics announced initial closing of a series b preferred financing round of up to $18.4 million with co as lead investor.

Nantkwest announces FDA grant of orphan drug designation

Nantkwest Inc <NK.O>:Nantkwest announces FDA grant of orphan drug designation for the company's ank natural killer cell therapy in merkel cell carcinoma.

NantKwest says FDA authorized co's IND for early-stage study

NantKwest Inc <NK.O> - :NantKwest - U.S. FDA has authorized co's IND for its first-in-human, high-affinity natural killer (haNK) cell therapy Phase I clinical study.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up